AUAUniversity

AUA2023: Refractory Overactive Bladder: How To Select 3rd Line Therapies and Optimize Outcomes

CME Available: https://auau.auanet.org/node/38287

CME Expiration Date: May, 2024

ACKNOWLEDGEMENTS

Independent educational grant support provided by:

Astellas

Urovant Sciences, Inc.

AUA2023: Prostate Cancer Diagnosis

CME Available: https://auau.auanet.org/node/38302

CME Expiration Date: May, 2024

ACKNOWLEDGEMENTS

Independent educational grant support provided by:

Astellas

AstraZeneca

Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Lantheus Medical Imaging

Merck & Co., Inc.

Pfizer, Inc.

Based on the findings from the 2022 AUA global survey and needs assessment in bladder cancer, the AUA has developed this new series of virtual courses to update urologists on the latest advancements in bladder cancer care. This course will address new and emerging treatment options for non‐muscle invasive (NMIBC) and muscle‐invasive bladder cancer (MIBC) with a focus on identifying side effects and interventions, review of guidelines specific to first and second line therapies, timing and usage of neoadjuvant and adjuvant systemic therapy, BCG shortage and the urologists role in clinical trial enrollment. Currently available agents as well as those in development will be discussed.

CME Available: https://auau.auanet.org/node/38615

Release Date: June, 2023

Expiration Date: June, 2024

ACKNOWLEDGEMENTS

This educational series is supported by an independent educational grant from AstraZeneca.

After participating in this educational series, participants will be able to:

1. Delineate key factors to risk stratify patients with NMIBC and MIBC.

2. Review guidelines focused on first‐ and second‐line therapies for NMIBC and MIBC.

3. Describe emerging treatment options with intravesical and systemic therapies for patients in an era of BCG shortage and for patients with BCG unresponsive disease and determine the appropriate timing and use of neoadjuvant and adjuvant systemic therapy for invasive bladder cancer.

4. Identify side effects and possible interventions to ameliorate side effects for these therapies.

5. Recognize the urologist’s role in clinical trials and how to overcome obstacles to clinical trial enrollment.

AUA2023: Advancing Gender Equity in Urology: Allyship for Men and Advocacy for Women

CME Available: https://auau.auanet.org/node/38337/

CME Expiration Date: May, 2024

ACKNOWLEDGEMENTS

Independent educational grant support provided by:

AstraZeneca

Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Merck & Co., Inc.

AUA2023: Genetics and Genomics of GU Malignancies: Applications into Your Clinical Practice

CME Available: https://auau.auanet.org/node/38317

CME Expiration Date: May, 2024

ACKNOWLEDGEMENTS

Independent educational grant support provided by:

Astellas

AstraZeneca

Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Lantheus Medical Imaging

Merck & Co., Inc.

Pfizer, Inc.

AUA2023: AUA Guidelines on Advanced Prostate Cancer

CME Available: https://auau.auanet.org/node/38297

CME Expiration Date: May, 2024

ACKNOWLEDGEMENTS

Independent educational grant support provided by:

Astellas

AstraZeneca

Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Lantheus Medical Imaging

Merck & Co., Inc.

Pfizer, Inc.

AUA2023: Diversity, Equity and Inclusion in Urology: What Do We Need to Know

CME Available: https://auau.auanet.org/node/38332/

CME Expiration Date: May, 2024

ACKNOWLEDGEMENTS

Independent educational grant support provided by:

AstraZeneca

Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Merck & Co., Inc.

AUA2023: The Changing Face of Advanced Prostate Cancer

CME Available: https://auau.auanet.org/node/38292

Release Date: May, 2023

Expiration Date: May, 2024

ACKNOWLEDGEMENTS

Independent educational grant support provided by:

Astellas

AstraZeneca

Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Lantheus Medical Imaging

Merck & Co., Inc.

Pfizer, Inc.

AUA2023: Contemporary Pharmacotherapy for OAB 2023

CME Available: https://auau.auanet.org/node/38282

Release Date: May, 2023

Expiration Date: May, 2024

ACKNOWLEDGEMENTS

Independent educational grant support provided by:

Astellas

Urovant Sciences, Inc.

LEARNING OBJECTIVES

At the conclusion of this activity, participants will be able to:

1. Define the similarities and differences between the various oral pharmacotherapies for OAB.

2. Review the principles of physiology and pharmacotherapy for currently available agents, including the antimuscarinics and beta3 agonists and combination therapy.

3. Explain the importance of setting proper patient expectations regarding treatment of OAB and the potential need for sequential and even additive therapies.

4. Analyze the clinical (and theoretical) advantages and limitations of currently available agents.

5. Discuss potential future pharmacological pathways and therapies for OAB.

Live from AUA2023: Highlights in BPH is a panel discussion filmed during the 2023 AUA Annual Meeting!

CME Available: https://auau.auanet.org/node/38008

Release Date: May, 2023

Expiration Date: May, 2024

ACKNOWLEDGEMENTS

This educational activity is supported by independent educational grants from:

Cook Medical, LLC.

Olympus Corporation of the Americas